Bcwm LLC Makes New $4.26 Million Investment in Pfizer Inc. (NYSE:PFE)

Bcwm LLC acquired a new position in shares of Pfizer Inc. (NYSE:PFE - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 160,725 shares of the biopharmaceutical company's stock, valued at approximately $4,264,000. Pfizer accounts for approximately 1.5% of Bcwm LLC's portfolio, making the stock its 28th biggest holding.

Other large investors also recently made changes to their positions in the company. United Bank lifted its holdings in shares of Pfizer by 3.7% during the 3rd quarter. United Bank now owns 35,599 shares of the biopharmaceutical company's stock valued at $1,030,000 after buying an additional 1,277 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. lifted its stake in Pfizer by 67.4% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 14,801 shares of the biopharmaceutical company's stock valued at $428,000 after acquiring an additional 5,959 shares during the last quarter. FMR LLC grew its position in Pfizer by 3.1% in the third quarter. FMR LLC now owns 14,478,489 shares of the biopharmaceutical company's stock worth $419,007,000 after acquiring an additional 435,311 shares in the last quarter. Quantbot Technologies LP acquired a new position in shares of Pfizer during the 3rd quarter worth $1,685,000. Finally, Rockefeller Capital Management L.P. raised its holdings in shares of Pfizer by 2.0% during the 3rd quarter. Rockefeller Capital Management L.P. now owns 1,630,089 shares of the biopharmaceutical company's stock valued at $47,169,000 after purchasing an additional 32,524 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company's stock.

Remove Ads

Insider Transactions at Pfizer

In related news, Director Ronald E. Blaylock acquired 19,457 shares of the company's stock in a transaction on Thursday, February 13th. The stock was purchased at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the purchase, the director now directly owns 27,707 shares of the company's stock, valued at $710,684.55. The trade was a 235.84 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 0.06% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several research firms have weighed in on PFE. Hsbc Global Res upgraded Pfizer to a "strong-buy" rating in a report on Monday, March 10th. Bank of America reissued a "neutral" rating and issued a $29.00 price objective on shares of Pfizer in a research note on Tuesday, December 10th. UBS Group decreased their target price on Pfizer from $31.00 to $29.00 and set a "neutral" rating for the company in a research report on Wednesday, January 8th. Citigroup dropped their price target on shares of Pfizer from $30.00 to $29.00 and set a "neutral" rating on the stock in a research report on Tuesday, January 28th. Finally, Truist Financial decreased their price objective on shares of Pfizer from $36.00 to $32.00 and set a "buy" rating for the company in a report on Wednesday, December 18th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating, six have issued a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Pfizer has a consensus rating of "Moderate Buy" and a consensus price target of $31.92.

Pfizer Stock Performance

Shares of NYSE PFE traded down $0.82 during trading hours on Tuesday, reaching $24.53. The stock had a trading volume of 53,500,077 shares, compared to its average volume of 39,152,503. Pfizer Inc. has a twelve month low of $24.48 and a twelve month high of $31.54. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The business's fifty day moving average is $26.05 and its two-hundred day moving average is $26.88. The company has a market cap of $139.09 billion, a price-to-earnings ratio of 17.39, a PEG ratio of 0.64 and a beta of 0.61.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, topping analysts' consensus estimates of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company had revenue of $17.76 billion during the quarter, compared to the consensus estimate of $17.26 billion. During the same period last year, the firm earned $0.10 EPS. The firm's revenue for the quarter was up 24.7% compared to the same quarter last year. As a group, research analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.